electroCore

Aging Population Will Expand gammaCore Adoption For Neuromodulation

AnalystHighTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

12 Aug 25

Updated

16 Aug 25

AnalystHighTarget's Fair Value

US$25.20

79.2% undervalued

16 Aug

US$5.24

-14.2%

13.3%

Author's Valuation

US$25.2

79.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$25.2

79.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

24.45%

Medical Equipment revenue growth rate

0.45%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.71%

Calculation

US$27.42m

Earnings '28

14.18x

PE Ratio '28

US$388.73m

Market Cap '28

US$388.73m

Market Cap '28

12.34m

No. shares '28

US$31.49

Share Price '28

US$31.49 Share Price '28

Discounted to 2025 @ 7.71% p.a.

US$25.20

Fair Value '25